Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma

British Journal of Haematology

Volumn 128, Issue 6, 2005, Pages 813-819

  Pedersen, Lars Møller ^a   Jürgensen, Gitte W ^a   Johnsen, Hans E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Diffuse large B cell lymphoma; Immunohistochemistry; Inflammatory cytokines; International Prognostic Index; Prognosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOKINE; DAUNORUBICIN; INTERLEUKIN 6; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GENE EXPRESSION; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFLAMMATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 15944404916     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05393.x     Document Type: Article

References (28)

1. Airoldi, I., Guglielmino, R., Ghiotto, F., Corcione, A., Facchetti, P., Truini, M. & Pistoia, V. (2001) Cytokine gene expression in neoplastic B cells from human mantle cell, follicular, and marginal zone lymphomas and in their postulated normal counterparts. Cancer Research, 61, 1285-1290.
2. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, Jr. J., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. & Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-511.
3. Bairey, O., Zimra, Y., Shaklai, M. & Rabizadeh, E. (2001) Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 113, 400-406.
4. Barrans, S.L., Carter, I., Owen, R.G., Davies, F.E., Patmore, R.D., Haynes, A.P., Morgan, G.J. & Jack, A.S. (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood, 99, 1136-1143.
5. Bertolini, F., Paolucci, M., Peccatori, F., Cinieri, S., Agazzi, A., Ferrucci, P.F., Cocorocchio, E., Goldhirsch, A. & Martinelli, G. (1999) Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. British Journal of Haematology, 106, 504-509.
6. Colomo, L., Lopez-Guillermo, A., Perales, M., Rives, S., Martinez, A., Bosch, F., Colomer, D., Falini, B., Montserrat, E. & Campo, E. (2003) Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 101, 78-84.
7. Evan, G.I. & Vousden, K.H. (2001) Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-348.
8. Gascoyne, R.D., Adomat, S.A., Krajewski, S., Krajewska, M., Horsman, D.E., Tolcher, A.W., O'Reilly, S.E., Hoskins, P., Coldman, A.J., Reed, J.C. & Connors, J.M. (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood, 90, 244-251.
9. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
10. Jaffe, E.S., Harris, N.L., Vardiman, J.W. & Stein, H. (2001) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. IARC Press, Lyon, France.
11. Juszczynski, P., Kalinka, E., Bienvenu, J., Woszczek, G., Borowiec, M., Robak, T., Kowalski, M., Lech-Maranda, E., Baseggio, L., Coiffier, B., Salles, G. & Warzocha, K. (2002) Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood, 100, 3037-3040.
12. Lech-Maranda, E., Baseggio, L., Bienvenu, J., Charlot, C., Berger, F., Rigal, D., Warzocha, K., Coiffier, B. & Salles, G. (2004) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood, 103, 3529-3534.
13. Lossos, I.S., Czerwinski, D.K., Alizadeh, A.A., Wechser, M.A., Tibshirani, R., Botstein, D. & Levy, R. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New England Journal of Medicine, 350, 1828-1837.
14. Niitsu, N., Okamato, M., Nakamine, H., Yoshino, T., Tamaru, J., Nakamura, S., Higashihara, M. & Hirano, M. (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. European Journal of Haematology, 68, 91-100.
15. Nor, J.E., Christensen, J., Mooney, D.J. & Polverini, P.J. (1999) Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. American Journal of Pathology, 154, 375-384.
16. Pazgal, I., Zimra, Y., Tzabar, C., Okon, E., Rabizadeh, E., Shaklai, M. & Bairey, O. (2002) Molecular and cellular pathology expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma. British Journal of Cancer, 86, 1770-1775.
17. Pedersen, L.M. & Sørensen, P.G. (2003) Mediators of inflammation correlate with microalbuminuria in patients with non-Hodgkin's lymphoma. British Journal of Haematology, 121, 275-279.
18. Rimsza, L.M., Roberts, R.A., Miller, T.P., Unger, J.M., LeBlanc, M., Braziel, R.M., Weisenberger, D.D., Chan, W.C., Muller-Hermelink, H.K., Jaffe, E.S., Gascoyne, R.D., Campo, E., Fuchs, D.A., Spier, C.M., Fisher, R.I., Delabie, J., Rosenwald, A., Staudt, L.M. & Grogan, T.M. (2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood, 103, 4251-4258.
19. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. & Staudt, L.M. Lymphoma/Leukemia Molecular Profiling Project (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 1937-1947.
20. Saez, A.I., Saez, A.J., Artiga, M.J., Perez-Rosado, A., Camacho, F.I., Diez, A., Garcia, J.F., Fraga, M., Bosch, R., Rodriguez-Pinilla, S.M., Mollejo, M., Romero, C., Sanchez-Verde, L., Pollan, M. & Piris, M.A. (2004) Building an outcome predictor model for diffuse large B-cell lymphoma. American Journal of Pathology, 164, 613-622.
21. Salles, G., Bienvenu, J., Bastion, Y., Barbier, Y., Doche, C., Warzocha, K., Gutowski, M.C., Rieux, C. & Coiffier, B. (1996) Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. British Journal of Haematology, 93, 352-359.
22. Salven, P., Teerenhovi, L. & Joensuu, H. (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood, 90, 3167-3172.
23. Salven, P., Teerenhovi, L. & Joensuu, H. (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood, 94, 3334-3339.
24. Salven, P., Orpana, A., Teerenhovi, L. & Joensuu, H. (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood, 96, 3712-3718.
25. Seymour, J.F., Talpaz, M., Cabanillas, F., Wetzler, M. & Kurzrock, R. (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. Journal of Clinical Oncology, 13, 373-382.
26. Shipp, M.A., Harrington, D.P., Anderson, J.R., Armitage, J.O., Bonadonna, G., Brittinger, G., Cabanillas, F., Canellos, G.P., Coiffier, B., Connors, J.M., Cowan, R.A., Crowther, D., Dahlberg, S., Engelhard, M., Fisher, R.I., Gisselbrecht, C., Horning, S.J., Lepage, E., Lister, T.A., Meerwaldt, J.H., Montserrat, E., Nissen, N.I., Oken, M.M., Peterson, B.A., Tondini, C., Velasquez, W.A. & Yeap, B.Y. (1993) The international non-hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987-994.
27. Warzocha, K., Salles, G., Bienvenu, J., Bastion, Y., Dumontet, C., Renard, N., Neidhardt-Berard, E.M. & Coiffier, B. (1997) Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. Journal of Clinical Oncology, 15, 499-508.
28. Warzocha, K., Ribeiro, P., Bienvenu, J., Roy, P., Charlot, C., Rigal, D., Coiffier, B. & Salles, G. (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood, 91, 3574-3581.